Rotigotine
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25NOS
- CAS Number
- 99755-59-6
- Unique Ingredient Identifier
- 87T4T8BO2E
- Background
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
...
- Indication
For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 40
- Registration Number
- NCT03103919
- Locations
- 🇺🇸
Pd0049 105, Fountain Valley, California, United States
🇺🇸Pd0049 109, Houston, Texas, United States
🇺🇸Pd0049 108, Winfield, Illinois, United States
Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 40
- Registration Number
- NCT03098368
Non Motors Aspects in De Novo Parkinson's Disease
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 199
- Registration Number
- NCT02786667
- Locations
- 🇫🇷
University Hospital of Grenoble, Grenoble, France
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT02728947
- Locations
- 🇺🇸
CNS Network, Long Beach, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Azienda Ospedaliera Cardinale G. Panico
- Target Recruit Count
- 80
- Registration Number
- NCT02103465
- Locations
- 🇮🇹
Ospedale "A. Perrino", Brindisi, Italy
🇮🇹Ospedale S. Giacomo, Monopoli, Bari, Italy
🇮🇹IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy
MIRT and Rotigotine in the Early Stage of PD
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
- Target Recruit Count
- 40
- Registration Number
- NCT02100176
- Locations
- 🇮🇹
Riabilitazione Neuromotoria, Istituto Scientifico di Montescano, Montescano, Pavia, Italy
🇮🇹Ospedale Generale di Zona "Moriggia-Pelascini", Gravedona, Como, Italy
Switching From Oral Dopamine Agonists to Rotigotine
- Conditions
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- John Winkelman, MD, PhD
- Target Recruit Count
- 21
- Registration Number
- NCT01976871
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 48
- Registration Number
- NCT01964573
Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 130
- Registration Number
- NCT01823770
- Locations
- 🇫🇷
UH Montpellier, Montpellier, France
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 122
- Registration Number
- NCT01782222
- Locations
- 🇸🇰
3801, Banska Bystrica, Slovakia
🇵🇱3506, Gdynia, Poland
🇦🇹3003, Linz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.